Loading stock data…
$9.10-0.57 (-5.89%)
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Absci Corporation in the Healthcare sector is trading at $9.10 with a market capitalization of $2.0B. Wall Street consensus targets $14.50 (10 analysts), implying a +59.3% move over the next 12 months. The stock is currently 25% below its 52-week high of $12.05, remaining 49.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $318,000↑ | $215,000↓ | $650,000↑ | $378,000↓ | $593,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.16M↓ | -$30.85M↑ | -$36.14M↓ | -$30.15M↑ | -$31.39M |
| Net Income | -$33.21M↓ | -$29.60M↓ | -$29.56M↓ | -$28.71M↑ | -$30.57M |
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bow...